Telomolecular is a regenerative medicine company focused on developing core intellectual property for which it has exclusive licenses from some of the USA's top research institutions. The Company's lead product candidates include nanoparticle delivery of compounds to treat the effects of ischemic stroke, reperfusion injuries and cardiovascular restenosis. In addition, the Company is developing a number of pioneering technologies to treat diseases of aging, chronic illness, cellular reconstruction and cancer.

Regenerative medicine is a rapidly expanding field. It consists of pioneering medical technologies that enable organisms to repair, replace, and regenerate aged, diseased, or damaged tissues, organs, and cellular structures. The market estimates for the regenerative medicine sector are approximately $5B for 2008 and are expected to grow to $11B by 2010 and $300B by 2020.

In early studies conducted at The Cleveland Clinic in 2008 the Company's lead product candidate was shown to reduce the necrotic effects of stroke ischemia in 75% of the subjects studied. The Company expects to move into further clinical studies and is optimistic that it may begin early human trials in 2009.

"More than 700,000 Americans will experience a new or recurrent stroke this year and 160,000 of them will die." 'Stroke leave many Americans unable to work or carry out their previous activities,' said Dr. Goldstein. "Because stroke leaves so many disabled it is also a threat to our economy-it is estimated to cost our nation $53.6 billion this year."

-The American Heart Association 2004

Telomolecular's second product candidate, the nanoparticle delivery of the p53 protein, is targeted at post angioplasty restenosis. Early stage testing has shown this product is effective in inhibiting restenosis with a corresponding increase in the lumen diameter. The Company plans to engage in further clinical study with the intention of moving into human trials in late 2009.

Telomolecular released its first commercial product in December of 2007. bĭm·ə·nē is a novel cosmeceutical product targeting the aesthetic medical market. bĭm·ə·nē utilizes the Company's nanotechnology capability to load recombinant human collagen type III and Hyaluronic acid into nanoparticles and deliver them topically as an aesthetic cream for anti-aging purposes.

Telomolecular's objective is to become a dominant company in these emerging markets. Our mission is to develop and commercialize regenerative medical technologies in large markets with unmet needs. Our strategy is to continue to aggregate a portfolio of compelling intellectual property. The financial strategy is to create one or more international entities, capitalize the structure with institutional and early stage investors, and achieve liquidity with a continuous roll out of commercialization projects based upon current and planned acquisitions of technologies consistent with our mission.